HUBEI BIOCAUSE HEILEN PHARMACEUTICAL CO., LTD. Financials Hubei Biocause Heilen Pharmaceutical Co., Ltd.
Equities
301211
CNE100005782
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.2 CNY | +1.67% |
|
-7.15% | -30.11% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 9,026 | 8,316 | 6,264 |
| Enterprise Value (EV) 1 | 7,167 | 6,361 | 4,447 |
| P/E ratio | 55.3 x | 66.6 x | 35.7 x |
| Yield | 0.8% | 1.15% | 2.21% |
| Capitalization / Revenue | 16.7 x | 16.2 x | 9.45 x |
| EV / Revenue | 13.3 x | 12.4 x | 6.71 x |
| EV / EBITDA | 52.1 x | 66.5 x | 26.8 x |
| EV / FCF | 111 x | 62.2 x | -37.4 x |
| FCF Yield | 0.9% | 1.61% | -2.67% |
| Price to Book | 4.06 x | 3.65 x | 2.66 x |
| Nbr of stocks (in thousands) | 288,000 | 288,000 | 288,000 |
| Reference price 2 | 31.34 | 28.87 | 21.75 |
| Announcement Date | 27/04/22 | 24/04/23 | 22/04/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 517.1 | 660 | 592.9 | 540.6 | 514.9 | 663 |
| EBITDA 1 | 127.9 | 236.8 | 218.3 | 137.4 | 95.73 | 165.6 |
| EBIT 1 | 111.9 | 215.1 | 200.1 | 118.1 | 75.35 | 145.4 |
| Operating Margin | 21.64% | 32.59% | 33.75% | 21.84% | 14.63% | 21.93% |
| Earnings before Tax (EBT) 1 | 106.6 | 217 | 198.6 | 139.2 | 147.4 | 202.8 |
| Net income 1 | 47.74 | 100.3 | 168.1 | 121.6 | 125.7 | 176.1 |
| Net margin | 9.23% | 15.19% | 28.35% | 22.5% | 24.42% | 26.56% |
| EPS 2 | 0.2250 | 0.4667 | 0.7750 | 0.5667 | 0.4333 | 0.6100 |
| Free Cash Flow 1 | 8.4 | 374 | -39.94 | 64.84 | 102.2 | -118.8 |
| FCF margin | 1.62% | 56.67% | -6.74% | 11.99% | 19.85% | -17.92% |
| FCF Conversion (EBITDA) | 6.57% | 157.93% | - | 47.18% | 106.77% | - |
| FCF Conversion (Net income) | 17.6% | 372.95% | - | 53.3% | 81.29% | - |
| Dividend per Share | - | - | - | 0.2500 | 0.3333 | 0.4800 |
| Announcement Date | 01/06/21 | 01/06/21 | 01/06/21 | 27/04/22 | 24/04/23 | 22/04/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 17.9 | 343 | 346 | 1,860 | 1,955 | 1,817 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 8.4 | 374 | -39.9 | 64.8 | 102 | -119 |
| ROE (net income / shareholders' equity) | 25.9% | 41.6% | 28.3% | 8.32% | 5.59% | 7.6% |
| ROA (Net income/ Total Assets) | 11.9% | 19.4% | 16.1% | 4.71% | 1.95% | 3.6% |
| Assets 1 | 401.1 | 517 | 1,041 | 2,583 | 6,445 | 4,889 |
| Book Value Per Share 2 | 1.350 | 2.260 | 3.240 | 7.720 | 7.900 | 8.180 |
| Cash Flow per Share 2 | 0.3000 | 0.3300 | 0.4900 | 6.460 | 6.450 | 5.880 |
| Capex 1 | 25.1 | 32.3 | 13.4 | 21.1 | 76 | 187 |
| Capex / Sales | 4.85% | 4.9% | 2.26% | 3.9% | 14.75% | 28.13% |
| Announcement Date | 01/06/21 | 01/06/21 | 01/06/21 | 27/04/22 | 24/04/23 | 22/04/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -30.11% | 594M | |
| +45.82% | 754B | |
| +40.95% | 630B | |
| -6.16% | 352B | |
| +19.86% | 331B | |
| +9.32% | 298B | |
| +18.45% | 250B | |
| +11.88% | 217B | |
| -0.78% | 216B | |
| +5.90% | 164B |
- Stock Market
- Equities
- 301211 Stock
- Financials Hubei Biocause Heilen Pharmaceutical Co., Ltd.